Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

TOK-8801

Catalog No: tcsc0018158

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Specifications

CAS No:
105963-46-0

Formula:
$C_{17}H_{21}N_3OS$

Pathway:
Others

Target:
Others

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
315.43

Product Description

TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator.

In Vitro: TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator. TOK-

8801 augments the *in vitro* anti-SRBC PFC response of murine splenocytes in a bell-shaped manner. The stimulatory effect of TOK-8801 is observed at concentrations of 2.5×10^{-7} to 2.5×10^{-5} M and is diminished at 10^{-4} M. The cell-viability is not altered during the culture with TOK-8801 at any doses used in this experiment (10^{-7} to 10^{-4} M). TOK-8801 enhances the ^{3}H-TdR uptake of these responses in a bell-shaped manner, and effective concentrations of TOK-8801 are 10^{-7} to 10^{-5} M[1].

In Vivo: The anti-SRBC PFC response per spleen, which is prominently lowered by restraint-stress (P[1]. When TOK-8801 is administered orally at doses of 0.1 to 10 mg/kg, the number of plaque forming cell (PFC) significantly decreases or tends to decrease. Treatment of TOK-8801 at doses of 0.1 to 1 mg/kg causes significant suppression in the delayed-type hypersensitivity (DTH) reaction induced in high responder[2].